Berry Scented Hand Sanitizer Minnie label

Berry Scented Hand Sanitizer Minnie

Berry Scented Hand Sanitizer Minnie Recall

Get an alert when a recall is issued.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

History

There is currently no drug history available for this drug.

Other Information

There are no additional details available for this product.

Berry Scented Hand Sanitizer Minnie Manufacturers

  • Shenzhen Lantern Science Co., Ltd.
    Berry Scented Hand Sanitizer Minnie | Peniel World Co., Ltd.
    No Recall

    Berry Scented Hand Sanitizer Minnie | Peniel World Co., Ltd.

    Berry Scented Hand Sanitizer Minnie | Peniel World Co., Ltd.
  • Townley, Inc.
    Berry Scented Hand Sanitizer Minnie | Trigen Laboratories, Llc
    No Recall

    Berry Scented Hand Sanitizer Minnie | Trigen Laboratories, Llc

    Berry Scented Hand Sanitizer Minnie | Trigen Laboratories, Llc
    2.1 General Considerations

    Dose once daily. The dosage can be increased after 1 to 2 weeks of therapy to a maximum of one 10/320mg tablet once daily as needed to control blood pressure. The majority of the antihypertensive effect is attained within 2 weeks after initiation of therapy or a change in dose.
    Amlodipine and valsartan tablets may be administered with or without food.
    Amlodipine and valsartan tablets may be administered with other antihypertensive agents.


    2.2 Add-on Therapy

    A patient whose blood pressure is not adequately controlled with amlodipine (or another dihydropyridine calcium-channel blocker) alone or with valsartan (or another angiotensin II receptor blocker) alone may be switched to combination therapy with amlodipine and valsartan tablets.

    A patient who experiences dose-limiting adverse reactions on either component alone may be switched to amlodipine and valsartan tablets containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. The clinical response to amlodipine and valsartan tablets should be subsequently evaluated and if blood pressure remains uncontrolled after 3 to 4 weeks of therapy, the dose may be titrated up to a maximum of 10/320 mg.

    2.3 Replacement Therapy

    For convenience, patients receiving amlodipine and valsartan from separate tablets may instead wish to receive tablets of amlodipine and valsartan tablets containing the same component doses.

    2.4 Initial Therapy

    A patient may be initiated on amlodipine and valsartan tablets if it is unlikely that control of blood pressure would be achieved with a single agent. The usual starting dose is amlodipine and valsartan tablets 5/160 mg once daily in patients who are not volume-depleted.